This article investigated the risk of new primary (cancer that does not originate in another organ) cancers after treatment with carbon ion radiotherapy (CIRT), photon radiotherapy (PRT) or surgery for localized prostate cancer (PC).

The authors concluded that CIRT is associated with a lower risk of new primary cancers vs PRT. 

This study examined how long hormonal therapy should continue in patients who have received radiotherapy after prostate removal surgery (prostatectomy). This study concluded that patients with a higher number of risk risk factors should receive HT for a longer period of time. 

This study evaluated the safety and effectiveness of sipuleucel-T (Provenge) treatment in patients with metastatic castration-resistant prostate cancer (mCRPC). The authors found that the average survival after sipuleucel-T treatment was 30.7 months and that 13.7% of patients experienced side effects.

This study examined the impact of different prostate cancer treatments on quality of life. This study concluded stereotactic body radiotherapy (SBRT) and active surveillance resulted in a similar quality of life in the long term.

This article investigated the link between blood glucose control and long-term prostate cancer (PC) outcomes in men with diabetes mellitus (DM) who are having a radical prostatectomy (RP; complete removal of the prostate). 

The authors concluded that a worse blood glucose control was associated with metastases and castration-resistant prostate cancer (CRPC; PC that does worsens in spite of hormonal therapy). 

This study examined if exposure to certain environmental chemicals is linked to prostate cancer recurrence. This study concluded that environmental estrogens may increase the risk of prostate cancer recurrence.

This study reviewed the role of external beam radiation therapy in the treatment of prostate cancer. 

This article investigated the safety and effectiveness of docetaxel (Taxotere)-based chemotherapy in combination with dexamethasone (Decadron) for the treatment of castration-resistant prostate cancer (CRPC). The authors concluded that this treatment combination is a safe and effective treatment option for advanced prostate cancer.  

This article investigated the safety and effectiveness of salvage high-intensity focused ultrasound (S-HIFU) in patients with locally recurrent prostate cancer (LRPC; cancer which has come back and is confined to the prostate gland) after treatment with low dose rate brachytherapy (BT). 

The authors concluded that S-HIFU is an effective treatment option to increase survival with a risk of more side effects.

This study aimed to evaluate the safety and effectiveness of radium-223 (Xofigo, formerly known as Alpharadin) in patients with advanced prostate cancer that has spread to the bones and who have had this treatment previously. This study found that re-treatment with radium-223 was well tolerated and with good results.